Risk factor
Very poor trading liquidity
Profitability factor
Overvalued vs peers
About
Established in 1989 and headquartered in Taipei City, Taiwan, BIONET Corp. is a global leader in umbilical cord blood preservation, serving clients across Taiwan and internationally. The company provides a comprehensive suite of stem cell banking services, encompassing the storage of general stem cells, mesenchymal stem cells, dental stem cells, adipose stem cells, and peripheral blood stem cells combined with immune cells. Beyond its core stem cell preservation, BIONET also conducts genetic testing services. Its product offerings further extend to anti-aging solutions leveraging stem cell technology, alongside its unique ANIKINE series. Additionally, the company is a pioneer in offering Exosome, an innovative cell-free therapeutic approach.
Company Valuation
From both historical and forecast perspectives, the stock is overpriced compared to similar stocks. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBITDA